modified with polyethylene glycol delivered into the mammal it can combine with ergosterol of fungus cell membranes while not combine with cholesterol of mammal cell membranes the purposes of inhibiting fungal infection with amphotericin b and reducing damage of amphotericin b for the mammal are achieved the purpose of modifying the sterol with polyethylene glycol is to provide polymeric micelles formed of amphotericin b encapsulated by the polyethylene glycol sterol carrier with a hydrophilic end such that the polymeric micelles of amphotericin b can be dissolved in water and will not combine with proteins in blood in a large quantity as a consequence the kidney poisoning can be reduced and the polymeric micelles of amphotericin b can follow lipid to be intake by monocyte the polymeric micelles of amphotericin b encapsulated by the sterol modified with polyethylene glycol can be dispersed in a proper solvent for preservation the proper solvent is a co solvent including methanol acetone methanol acetonitrile and ethanol acetone the mixture ratio of the aforementioned co solvent is in the range of 1 1 to 1 5 preferably 1 2 the present invention provides a method for manufacturing an antifungal formulation which includes the steps of a selecting a sterol whose affinity for amphotericin b is between ergosterol and cholesterol when modified with polyethylene glycol b modifying the aforementioned sterol with polyethylene glycol in order that polyethylene glycol is covalently attached to u2014 oh group of the sterol directly or indirectly.